Literature DB >> 7321565

Inflammatory cancer of the breast: analysis of 114 cases.

F Bozzetti, R Saccozzi, M De Lena, B Salvadori.   

Abstract

One hundred and fourteen cases of inflammatory breast cancer were reviewed. Actuarial survival curves, independent of the stage and type of treatment, showed a median survival of less than 15 months. As regards the three different subgroups of 80, 14, and 20 women, N0-1-2M0, N3M1 respectively, the acutuarial survival curves showed figures of median survival that decreased from 14 to 4 months, according to the extent of the disease. Survival rates for the subgroups of patients treated by radical mastectomy, radical mastectomy followed by radiotherapy, and radiotherapy alone were not significantly different. Neither the more sophisticated therapeutic approaches intended to modify the hormonal medium of the patients, nor the combined chemotherapy plus radiotherapy, proved to be successful. Inflmmatory breast cancer should be considered a systemic disease; consequently, in spite of discouraging results, only a systemic therapeutic approach, consisting of aggressive combination chemotherapy and perhaps immunostimulation, seems worthwhile.

Entities:  

Mesh:

Year:  1981        PMID: 7321565     DOI: 10.1002/jso.2930180405

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Tari A King; Monica Morrow
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 2.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

Review 3.  Management of inflammatory breast cancer.

Authors:  S E Singletary; F C Ames; A U Buzdar
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

4.  Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

Authors:  Paul H Levine; Chia C Portera; Heather J Hoffman; Sherry X Yang; Mikiko Takikita; Quyen N Duong; Stephen M Hewitt; Sandra M Swain
Journal:  Clin Breast Cancer       Date:  2012-06-12       Impact factor: 3.225

5.  Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy.

Authors:  R L Bauer; E Busch; E Levine; S B Edge
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

6.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

Authors:  Ian J Bristol; Wendy A Woodward; Eric A Strom; Massimo Cristofanilli; Delora Domain; S Eva Singletary; George H Perkins; Julia L Oh; Tse-Kuan Yu; Welela Terrefe; Aysegul A Sahin; Kelly K Hunt; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

7.  Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?

Authors:  Anya Romanoff; Emily C Zabor; Oriana Petruolo; Michelle Stempel; Mahmoud El-Tamer; Monica Morrow; Andrea V Barrio
Journal:  Cancer       Date:  2018-10-11       Impact factor: 6.860

8.  Survival of women with inflammatory breast cancer: a large population-based study.

Authors:  S Dawood; X Lei; R Dent; S Gupta; B Sirohi; J Cortes; M Cristofanilli; T Buchholz; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2014-03-24       Impact factor: 32.976

Review 9.  Inflammatory Breast Cancer: A Literature Review.

Authors:  Fouzia Mamouch; Narjiss Berrada; Zineb Aoullay; Basma El Khanoussi; Hassan Errihani
Journal:  World J Oncol       Date:  2018-11-23

10.  Survival of breast cancer patients diagnosed during pregnancy or lactation.

Authors:  S Tretli; G Kvalheim; S Thoresen; H Høst
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.